Drug-Resistant mCRPC is GlycoMantra’s Lead Indications
Our first-in-class biologic drug GM101 has demonstrated efficacy in humanized mice xenografted with mCRPC. It suppresses drug-resistant mCRPC and increases animal survival through modulation of AR signaling.
We are seeking investment or pharma partnership for further development of our drug and clinical trials. Please click the link below for our short video pitch.
Maryland residents are eligible to receive Biotechnology Investment Incentive Tax Credit (BIITC). BIITC provides an income tax credit equal to 50% of an eligible investment up to $250,000 per fiscal year. For more information, see